Search Within

Neil Mukund Iyengar

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (29)
  2. Journal Article (13)
  3. Research Letter (1)
Groups
  1. Breast Medicine Service (43)
  2. Department of Medicine (43)
  3. Epidemiology and Biostatistics (43)
  4. Population Sciences Research Program (43)
  5. Solid Tumor Oncology Division (43)
  6. Survivorship Research (43)

More Groups

People
  1. Clifford Hudis (21)
  2. Chau Dang (20)
  3. Larry Norton (20)
  4. Sujata Patil (20)
  5. Shanu Modi (17)
  6. Jose Baselga (13)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (5)
  4. 2022 (7)
  5. 2021 (3)
  6. 2019 (3)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Blood (6)
  3. Cancer Research (5)
  4. Cancer (3)
  5. Clinical Lymphoma, Myeloma and Leukemia (3)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (16)
  2. American Society of Hematology (6)
  3. American Association for Cancer Research (5)
  4. Elsevier Inc. (5)
  5. Oxford University Press (3)
  6. Wiley Blackwell (3)

More Publishers

Results (43)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Biomarkers that predict sensitivity to heat shock protein 90 inhibitors
    Journal Article

    Jhaveri, K.; Chandarlapaty, S.; Iyengar, N.; Morris, P. G.; Corben, A. D.; Patil, S.; Akram, M.; Towers, R.; Sakr, R. A.; King, T. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: Overall survival and updated progression-free survival results from a phase II study
    Journal Article

    Smyth, L. M.; Iyengar, N. M.; Chen, M. F.; Popper, S. M.; Patil, S.; Wasserheit-Lieblich, C.; Argolo, D. F.; Singh, J. C.; Chandarlapaty, S.; Sugarman, S. M.; more...
    Breast Cancer Research and Treatment (2016)

    Fulltext@MSK | Save
  • Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience
    Meeting Abstract

    Singh, J. C.; Sugarman, S.; Jones, L.; Boafo, C.; Patil, S.; Schweber, S.; Yu, A.; Argolo, D.; Modi, S.; Iyengar, N.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • A pilot study of dose-dense paclitaxel with trastuzumab and lapatinib for node-negative HER2-overexpressed breast cancer
    Journal Article

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S. M.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G. M.; Drullinsky, P. R.; Gajria, D.; Goldfarb, S. B.; Comen, E. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result
    Meeting Abstract

    Smyth, L. M.; Iyengar, N. M.; Chandarlapaty, S.; Sugarman, S.; Comen, E. A.; Drullinsky, P.; Sklarin, N. T.; Traina, T. A.; Troso-Sandoval, T. A.; Patil, S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center
    Meeting Abstract

    Fontes Santos De Teive Argolo, D.; Smyth, L. M.; Iyengar, N. M.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)
    Meeting Abstract

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G.; Drullinsky, P.; Fasano, J.; Gajria, D.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC)
    Meeting Abstract

    Morris, P. G.; Iyengar, N. M.; Patil, S.; Chen, C.; Abbruzzi, A.; Lehman, R. J.; Steingart, R.; Oeffinger, K. C.; Lin, N.; Moy, B.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
    Meeting Abstract

    Iyengar, N. M.; Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save